Short Interest in Surrozen, Inc. (NASDAQ:SRZN) Grows By 33.9%

Surrozen, Inc. (NASDAQ:SRZN) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 45,400 shares, an increase of 33.9% from the November 30th total of 33,900 shares. Approximately 1.9% of the company’s shares are sold short. Based on an average trading volume of 33,200 shares, the days-to-cover ratio is currently 1.4 days.

Surrozen Stock Down 6.0 %

Shares of Surrozen stock traded down $0.88 on Friday, hitting $13.90. 48,850 shares of the company’s stock traded hands, compared to its average volume of 18,479. The company has a fifty day moving average of $10.44 and a two-hundred day moving average of $9.77. Surrozen has a one year low of $6.00 and a one year high of $16.19.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($2.77) by $2.33. The company had revenue of $10.00 million for the quarter. Equities research analysts anticipate that Surrozen will post -7.16 EPS for the current year.

Institutional Investors Weigh In On Surrozen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. CVI Holdings LLC purchased a new position in shares of Surrozen in the 2nd quarter worth approximately $711,000. Stonepine Capital Management LLC bought a new position in Surrozen in the 2nd quarter valued at $724,000. Nantahala Capital Management LLC purchased a new stake in shares of Surrozen during the 2nd quarter valued at $2,050,000. Finally, Armistice Capital LLC bought a new stake in shares of Surrozen during the 2nd quarter worth $2,080,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.